Apeloa Pharmaceutical Co Ltd (000739) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Apeloa Pharmaceutical Co Ltd (000739) has a cash flow conversion efficiency ratio of 0.056x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥366.84 Million ≈ $53.68 Million USD) by net assets (CN¥6.49 Billion ≈ $950.30 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Apeloa Pharmaceutical Co Ltd - Cash Flow Conversion Efficiency Trend (1998–2024)
This chart illustrates how Apeloa Pharmaceutical Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read 000739 liabilities breakdown for a breakdown of total debt and financial obligations.
Apeloa Pharmaceutical Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Apeloa Pharmaceutical Co Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Ningbo Huaxiang Electronic Co Ltd
SHE:002048
|
0.039x |
|
Shaanxi Lighte Optoelectronics Material Co. Ltd. A
SHG:688150
|
N/A |
|
CCC Intelligent Solutions Holdings Inc.
NASDAQ:CCC
|
0.067x |
|
Solar Applied Materials Technology
TWO:1785
|
0.003x |
|
Cellebrite DI
NASDAQ:CLBT
|
0.170x |
|
China World Trade Center Co Ltd
SHG:600007
|
0.059x |
|
Shurgard Self Storage SA
BR:SHUR
|
0.019x |
|
Adecco Group AG Class N
SW:ADEN
|
0.141x |
Annual Cash Flow Conversion Efficiency for Apeloa Pharmaceutical Co Ltd (1998–2024)
The table below shows the annual cash flow conversion efficiency of Apeloa Pharmaceutical Co Ltd from 1998 to 2024. For the full company profile with market capitalisation and key ratios, see Apeloa Pharmaceutical Co Ltd stock valuation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | CN¥6.75 Billion ≈ $987.72 Million |
CN¥1.21 Billion ≈ $176.88 Million |
0.179x | +8.18% |
| 2023-12-31 | CN¥6.23 Billion ≈ $911.71 Million |
CN¥1.03 Billion ≈ $150.92 Million |
0.166x | -31.10% |
| 2022-12-31 | CN¥5.52 Billion ≈ $807.64 Million |
CN¥1.33 Billion ≈ $194.05 Million |
0.240x | +98.74% |
| 2021-12-31 | CN¥5.06 Billion ≈ $740.44 Million |
CN¥611.75 Million ≈ $89.52 Million |
0.121x | -49.90% |
| 2020-12-31 | CN¥4.39 Billion ≈ $642.49 Million |
CN¥1.06 Billion ≈ $155.04 Million |
0.241x | -33.15% |
| 2019-12-31 | CN¥3.77 Billion ≈ $551.37 Million |
CN¥1.36 Billion ≈ $199.02 Million |
0.361x | +44.97% |
| 2018-12-31 | CN¥3.34 Billion ≈ $489.37 Million |
CN¥832.69 Million ≈ $121.85 Million |
0.249x | +261.97% |
| 2017-12-31 | CN¥3.05 Billion ≈ $446.31 Million |
CN¥209.80 Million ≈ $30.70 Million |
0.069x | -0.24% |
| 2016-12-31 | CN¥2.62 Billion ≈ $382.88 Million |
CN¥180.42 Million ≈ $26.40 Million |
0.069x | -62.22% |
| 2015-12-31 | CN¥2.42 Billion ≈ $353.65 Million |
CN¥441.16 Million ≈ $64.56 Million |
0.183x | -46.49% |
| 2014-12-31 | CN¥2.31 Billion ≈ $337.43 Million |
CN¥786.64 Million ≈ $115.11 Million |
0.341x | +232.78% |
| 2013-12-31 | CN¥1.86 Billion ≈ $271.86 Million |
CN¥190.45 Million ≈ $27.87 Million |
0.103x | -58.33% |
| 2012-12-31 | CN¥1.37 Billion ≈ $199.83 Million |
CN¥335.90 Million ≈ $49.15 Million |
0.246x | +9.18% |
| 2011-12-31 | CN¥806.67 Million ≈ $118.04 Million |
CN¥181.74 Million ≈ $26.59 Million |
0.225x | +50.49% |
| 2010-12-31 | CN¥808.57 Million ≈ $118.32 Million |
CN¥121.05 Million ≈ $17.71 Million |
0.150x | -42.88% |
| 2009-12-31 | CN¥794.78 Million ≈ $116.30 Million |
CN¥208.30 Million ≈ $30.48 Million |
0.262x | +112.87% |
| 2008-12-31 | CN¥768.11 Million ≈ $112.40 Million |
CN¥94.57 Million ≈ $13.84 Million |
0.123x | -46.98% |
| 2007-12-31 | CN¥750.11 Million ≈ $109.76 Million |
CN¥174.20 Million ≈ $25.49 Million |
0.232x | -33.61% |
| 2006-12-31 | CN¥455.77 Million ≈ $66.69 Million |
CN¥159.43 Million ≈ $23.33 Million |
0.350x | +64.87% |
| 2005-12-31 | CN¥411.93 Million ≈ $60.28 Million |
CN¥87.40 Million ≈ $12.79 Million |
0.212x | +65.59% |
| 2004-12-31 | CN¥371.08 Million ≈ $54.30 Million |
CN¥47.54 Million ≈ $6.96 Million |
0.128x | -60.01% |
| 2003-12-31 | CN¥328.83 Million ≈ $48.12 Million |
CN¥105.36 Million ≈ $15.42 Million |
0.320x | +3160.50% |
| 2002-12-31 | CN¥286.40 Million ≈ $41.91 Million |
CN¥2.81 Million ≈ $411.85K |
0.010x | +547.91% |
| 2001-12-31 | CN¥259.70 Million ≈ $38.00 Million |
CN¥-569.79K ≈ $-83.38K |
-0.002x | -109.77% |
| 2000-12-31 | CN¥315.13 Million ≈ $46.11 Million |
CN¥7.08 Million ≈ $1.04 Million |
0.022x | +133.71% |
| 1999-12-31 | CN¥307.93 Million ≈ $45.06 Million |
CN¥-20.52 Million ≈ $-3.00 Million |
-0.067x | -154.92% |
| 1998-12-31 | CN¥248.02 Million ≈ $36.29 Million |
CN¥30.10 Million ≈ $4.40 Million |
0.121x | -- |
About Apeloa Pharmaceutical Co Ltd
Apeloa Pharmaceutical Co.,Ltd provides raw materials and intermediates to various pharmaceutical factories in the People's Republic of China and internationally. It operates through API, CDMO, and Pharmaceutical segments. The company offers API intermediates business, which includes cephalosporin, penicillin, psychotropic, cardiovascular and cerebrovascular, and veterinary API intermediates serie… Read more